Whether fezolinetant has been included in medical insurance and interpretation of related policies

As of2025, fezolinetant (Fezolinetant) has not been officially launched in mainland China, and therefore has not yet been included in the national medical insurance directory. This drug is a non-hormone selective neurokinin 3 receptor (NK3R) antagonist, mainly used to relieve menopausal-related vasomotor symptoms, such as hot flashes and night sweats. Because it has shown good efficacy in treating symptoms of menopausal women, it has gradually gained widespread attention in the European and American markets, and has been approved for marketing in the United States and other countries.

At present, fezonatant is still in the approval or clinical research stage in China. The National Medical Insurance Administration has not yet included it in the medical insurance catalog, and there is no clear timetable for its inclusion. This means that domestic patients cannot purchase drugs directly through formal channels in hospitals or pharmacies, nor can they enjoy medical insurance reimbursement policies. If they need medication, patients can only obtain it through cross-border medical institutions or overseas direct mail, which imposes certain restrictions on some patients with limited economic conditions or poor information channels.

Although it has not yet been launched in China, generic versions are available in overseas markets. It is understood that Laos Lucius Pharmaceutical Factory has launched a generic version of Fezonatant with the specifications of 45mg×30 tablets. The price is about 900 yuan. This version of the drug has the same ingredients as the original drug and is highly cost-effective, making it an important alternative channel for domestic patients to obtain the drug. However, it is recommended that patients use it under the guidance of a doctor to avoid side effects or dosage errors caused by self-medication.

Taken together, Fezonatant is currently not included in China’s medical insurance system and has not been officially launched in the country, so it does not currently meet the conditions for medical insurance reimbursement. Considering the unique role of this drug in relieving menopausal symptoms, if it can be successfully launched in the future, it is expected to be included as a treatment option in the field of women's health. While waiting for the introduction of drugs, patients can pay attention to official information. If they need to take drugs, it is recommended to choose guaranteed overseas channels and use them safely under the guidance of professional doctors.

Reference materials:https://www.drugs.com/